Development of Generic Drugs Market under the NHI Program in Taiwan: Knowledge, Attitudes, and Practices of Health Care Professional towards Generics Medication

• Main Authors: Cher Chang, 張竹君
• Other Authors: Yiing-Jeng Chou
• Format: Others
• Language: zh-TW
• Published: 2016
• Online Access: http://ndltd.ncl.edu.tw/handle/4298g4

碩士 === 國立陽明大學 === 醫務管理研究所 === 104 === Aging population, new advances in medical technology and increase in treatment costs have all contributes to the overall increase to health care costs year by year. To inhibit the increase costs of drug expenditure, the Department of NHI established various drug reimbursement schemes such as annual adjustment of drug price beginning in 1999, Drug Expenditure Target (DET) system, healthcare generics Triples, Cloud medical record system, HTA assessment of new drugs, and the recent initiative to balance the copayment burden of the cost of the original drugs. The purpose of these measures are to 1) to avoid medical costs being marginalized by drug costs, 2) to narrow the gap between drug payment and the actual transaction price, 3) to assess the fairness of the core price payment of new drugs, 4) to direct the fair trade of drugs from seller’s market to buyer’s market. In order to increase the confidence of generics drug prescription usage and the acceptance of the patient agents, the Ministry of Health and Welfare promoted the domestic pharmaceutical companies to join the Pharmaceutical Inspection Co-operation Scheme (PIC/S) by 2015. Domestic pharmaceutical industry on one hand must respond to the drug price cut policy and on the other hand faces the financial difficulties of upgrading the quality of its production. In the process of the change in regulations, of the 550 manufactures established under the 1982 GMP, only 114 sites are left after the 2015 implementation of PIC/S GMP. In the meantime, in 2016, imports from other countries with generics drugs (i.e. Israel TEVA, US Mylan or Novartis generics brand Sandoz, GSK generics brand Aspen), has exceeded 1000 in the Taiwan pharmaceutical market, making the generics drug market even more competitive. This study will evaluate the evolution of Taiwan's biotech pharmaceutical industry, focuses on the Central Health Administration Ministry of Health and Welfare’s development of health insurance drug reimbursement scheme over the years, explores the differences in the generics markets of Taiwan and the other countries, research through conducting survey of the health care professional awareness of domestic generics medication, attitudes and practices , hopefully to use the research results for future management strategies of Taiwan's biotech pharmaceutical industry and academic research management policy and the formulation of the health insurance drug price management policy.